We use cookies on our website. Carry on browsing if you’re happy with this or find out more



BioCentury ‘Emerging Company’ profile

BioCentury©, the respected Bioindustry newsletter, publishes an ‘Emerging Company’ profile on Kymab.

The 27 February 2012 issue of BioCentury© carries a profile of Kymab, in discussion with Chairman and CEO Andrew Sandham. Sandham describes the company's work to develop HK and HL strains and knock-in and knock-out systems to enhance antibody development.

Read the BioCentury Profile "Kymab: More mAb diversity".

Find out which events we'll be attending this year

View events